RATIONALE: Celecoxib may stop the growth of cancer by stopping blood flow to the tumor.
Erlotinib and celecoxib may stop the growth of tumor cells by blocking the enzymes necessary
for their growth. Combining celecoxib with erlotinib may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of celecoxib when
given together with erlotinib in treating patients with stage IIIB or stage IV non-small
cell lung cancer.
- Determine the biologically active dose of celecoxib administered with erlotinib in
patients with stage IIIB or IV non-small cell lung cancer.
- Determine the toxicity profile of this regimen in these patients.
- Determine the clinical activity of this regimen, in terms of reduction in tumor burden,
in these patients.
- Correlate biological endpoints with cyclooxygenase-2 and epidermal growth factor
receptor inhibition in patients treated with this regimen.
OUTLINE: This is a nonrandomized, dose-escalation study of celecoxib.
Patients receive oral erlotinib once daily and oral celecoxib twice daily on days 1-28.
Treatment repeats every 4 weeks for 2 courses in the absence of disease progression or
unacceptable toxicity. Patients with stable or responding disease may continue treatment
beyond 2 courses at the investigator's discretion.
Cohorts of 3-6 patients receive escalating doses of celecoxib until the maximum tolerated
dose (MTD) and biologically active dose (BAD) are determined. The MTD is defined as the dose
preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity (DLT).
The BAD is defined as the maximum decrease in the level of PGE_2 where no DLT occurs.
Patients are followed every 2 months.
PROJECTED ACCRUAL: A total of 21-27 patients will be accrued for this study.
- Histologically confirmed non-small cell lung cancer (NSCLC)
- Stage IIIB or IV
- Measurable disease
- Progressive disease after at least 2 prior standard chemotherapy regimens OR refused
- No active CNS metastases
- 21 and over
- ECOG 0-2
- Not specified
- Absolute neutrophil count at least 1,500/mm^3
- Platelet count at least 100,000/mm^3
- Bilirubin no greater than 1.5 mg/dL
- Transaminases no greater than 2.5 times upper limit of normal (ULN)
- PT and/or PTT no greater than 1.5 times ULN
- Creatinine no greater than 2 mg/dL
- No New York Heart Association class III or IV cardiac disease
- No myocardial infarction within the past year
- No symptomatic ventricular arrhythmia
- No symptomatic conduction abnormality
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- No prior gastrointestinal ulceration, bleeding, or perforation
- No hypersensitivity to celecoxib, sulfonamides, aspirin, other NSAIDs, or other
reagents used in this study
- No concurrent disease or medical condition that would preclude study treatment or
PRIOR CONCURRENT THERAPY:
- Not specified
- See Disease Characteristics
- More than 4 weeks since prior chemotherapy
- More than 4 weeks since prior corticosteroids
- No concurrent steroids (including chronic use)
- Concurrent topical steroids allowed
- More than 4 weeks since prior radiotherapy
- Not specified
- More than 4 weeks since prior non-cytotoxic investigational agents
- More than 3 days since prior nonsteroidal anti-inflammatory drugs (NSAIDs)
- No prior cyclooxygenase-2 (COX-2) inhibitors for metastatic NSCLC
- No prior epidermal growth factor receptor inhibitor for metastatic NSCLC
- No concurrent COX-2 inhibitors
- No concurrent NSAIDs
- No concurrent fluconazole or lithium